SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP · NASDAQ Global Market
+$0.45 today
Vol 0.11M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
40.3%
avg 40.3%
ROIC
-38.6%
avg -38.6%
ROA
-34.4%
avg -34.4%
Analysis
ROE is currently the strongest return metric at 40.3% versus its period average of 40.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Patrick H. Mooney | CEO & Director | $659,632.00 | — | 52 | — | — |
Chetan Pujara | Chief Research & Development Officer | $523,388.00 | — | 56 | — | — |
Malik Y. Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | $424,225.00 | — | 51 | — | — |
Glenn Sussman | Co-founder & Chief Technology Advisor | — | — | 62 | — | — |
James Robert Dennewill Jr. | Chief Operating Officer | — | — | 45 | — | — |
Nina Nguyen | Senior Vice President, Regulatory & Quality | — | — | — | — | — |
Rachel Gilette | Vice President of Human Resources | — | — | — | — | — |
Long Doan | VP & Head of Clinical Operations | — | — | — | — | — |
Jean-Frederic Viret | Chief Financial Officer | — | — | 60 | — | — |
Paul Yoo | Senior Vice President of Clinical Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages SGP?
SpyGlass Pharma, Inc. Common Stock (SGP) lists 10 active executives. The top listed executive is Chetan Pujara, Chief Research & Development Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.